Swiss Professional Services Stock News

Leadership changes and why they matter for Interroll Holding (SWX:INRN) Interroll Holding (SWX:INRN) has seen rapid shifts in its top ranks, with the Chief Operating Officer and Chief Technology Officer leaving and a new CTO, Ulrich Engenhardt, stepping in as the company reshapes key leadership roles. See our latest analysis for Interroll Holding. Those leadership changes come as the 90 day share price return stands at a 14.66% decline and the year to date share price return is a 7.10%...

ABB is preparing to report earnings on 29 January 2026, with investors closely watching margin commentary and order trends in its Electrification and Robotics segments. At the same time, ABB’s recent energy-efficiency partnership with E.ON has highlighted growing interest in its electrification solutions across European markets. With recent attention on ABB’s Electrification margins, we will explore how these developments could shape the company’s broader investment narrative. Trump's oil...

Nestlé (SWX:NESN) is drawing fresh attention as investors look ahead to its 19 February 2026 earnings release, while also weighing the recent infant nutrition recall and progress on a potential water business stake sale. See our latest analysis for Nestlé. After the recent recall headlines and the potential water business stake sale, short term sentiment has softened, with a 30 day share price return of 6.89% and a 90 day share price return of 9.54%. The 1 year total shareholder return is...

In January 2026, BELIMO Holding AG reported its 2025 revenue results, revealing accelerated sales growth of 23.3% in local currencies and total sales of CHF 1,121 million. This sharp step-up in growth compared with 2024 signals a meaningful strengthening in demand for BELIMO’s HVAC solutions across its end markets. We’ll explore how BELIMO’s sharply accelerating 2025 sales growth shapes the company’s investment narrative and future business positioning. These 9 companies survived and...

Roche Holding (SWX:ROG) has drawn fresh attention after Genentech, its U.S. subsidiary, committed about $2b to expand a Holly Springs, North Carolina biomanufacturing plant for metabolic and weight-loss therapies. See our latest analysis for Roche Holding. The Holly Springs commitment has arrived alongside a 28.36% 90 day share price return and a 30.82% one year total shareholder return. This suggests investors are responding to both near term news flow and a longer running shift in...

In January 2026, Galderma announced an arbitral tribunal confirmed the termination of its 2014 early-stage neuromodulator R&D partnership with Ipsen, while affirming that commercialization of Dysport/Azzalure, Alluzience, and Relfydess remains unaffected. At the same time, Galderma used major industry meetings such as TOXINS 2026 and IMCAS 2026 to highlight data underscoring the clinical strength and breadth of its neuromodulator portfolio, reinforcing its position in injectable...

Financing move and conference spotlight Swiss Life Holding (SWX:SLHN) recently completed a CHF 225 million floating rate bond offering and presented at Citi's European Insurance Conference 2026. These events put its funding approach and investor messaging in focus. See our latest analysis for Swiss Life Holding. The new bond issue and conference appearance come after a softer patch for the shares, with a 1-month share price return of 9.98% and year to date share price return of 11.16%. Longer...

By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual...

Key Insights Autoneum Holding's estimated fair value is CHF208 based on 2 Stage Free Cash Flow to Equity Autoneum...

There wouldn't be many who think DocMorris AG's ( VTX:DOCM ) price-to-sales (or "P/S") ratio of 0.3x is worth a mention...

Why Swiss Re is on watchlists ahead of earnings Swiss Re (SWX:SREN) is drawing increased attention as investors look ahead to its 27 February 2026 earnings release, focusing on the stock’s 4.75% dividend yield and recent trading activity. See our latest analysis for Swiss Re. Recent trading has been choppy, with a 30 day share price return of 7.39% and a 90 day share price return of an 18.66% decline. The 5 year total shareholder return of 111.08% points to momentum that has built over a...

Key Insights Mikron Holding's significant private companies ownership suggests that the key decisions are influenced by...

VAT Group (SWX:VACN) is back in focus after reporting preliminary 2025 figures, with Q4 net sales of CHF 257 million and orders of about CHF 305 million, alongside full year sales of CHF 1,073 million. See our latest analysis for VAT Group. The preliminary 2025 numbers arrive after a strong run in the shares, with the 30 day share price return of 32.99% and 90 day share price return of 48.48% contributing to a 1 year total shareholder return of 51.96%. This points to momentum building around...

India Energy Week debut puts Sensirion Holding (SWX:SENS) gas metering in focus Sensirion Holding (SWX:SENS) is drawing attention after announcing its first participation at India Energy Week 2026, where it will showcase its thermal mass gas metering technology and newly introduced SGM5304 gas meter module. The event spotlights Sensirion's role in gas metering, with more than 11 million meters installed globally and certification under harmonized standard EN 17526, as investors consider the...

Barry Callebaut recently reported a 22% fall in cocoa division sales volume for the quarter ended 30 November, citing weak global cocoa demand and a shift toward higher-return segments amid subdued grindings in Europe and Asia. At the same time, favorable growing conditions in West Africa and uncertainty around a CEO transition have sharpened questions about how the company balances sourcing, pricing and leadership stability in a soft cocoa market. Next, we will examine how the steep cocoa...

Earlier this week, Logitech unveiled its Rally AI Camera and Rally AI Camera Pro, AI-enabled conference cameras for large rooms that offer flexible mounting options, privacy shutters, workspace analytics via Logitech Sync, and prices starting at US$2,499, with availability planned from Spring and Summer 2026. By combining AI-powered room usage insights, automated scheduling relief from “ghost meetings,” and sustainability-focused design, these cameras position Logitech deeper inside how...

In January 2026, BKW AG held a special call to lower its 2025 EBIT guidance to CHF 540 million–CHF 560 million and introduce a 2026 EBIT range of CHF 650 million–CHF 750 million. This shift in near-term expectations versus a higher 2026 outlook highlights how BKW is recalibrating its earnings profile over the next two years. Next, we will examine how BKW’s reduced 2025 EBIT guidance shapes the company’s investment narrative and risk-reward profile for investors. Trump has pledged to...

Holcim (SWX:HOLN) came into focus after Goldman Sachs shifted its view on the shares from Buy to Neutral, following a strong rally that left the valuation looking full. See our latest analysis for Holcim. The latest CHF78.0 share price comes after a small 1 day share price decline, but that follows an 11.65% 90 day share price return and a very strong 1 year total shareholder return of 73.76%, pointing to momentum that has been building over a longer horizon. That performance also aligns with...

Nestlé has recently drawn attention with multiple developments, including an upcoming February 2026 earnings release, a recall of infant nutrition products over cereulide contamination concerns, reported progress toward selling a stake in its water business, and ongoing exposure to growth in markets such as India’s chocolate sector. Together, these events highlight how Nestlé is simultaneously managing product safety and portfolio reshaping while competing for long-term demand in...

Ypsomed Holding (SWX:YPSN) is back in focus after expanding its collaboration with Becton, Dickinson and Company on a 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe that is compatible with YpsoMate 5.5 autoinjectors. See our latest analysis for Ypsomed Holding. At a share price of CHF334.0, Ypsomed Holding has a 90 day share price return of 4.38% and a 5 year total shareholder return of 129.55%. This points to longer term momentum, despite a weaker 1 year total shareholder return of...

Sales acceleration puts BELIMO Holding (SWX:BEAN) in focus BELIMO Holding (SWX:BEAN) reported 2025 sales growth of 23.3% in local currencies, compared with 13.1% in 2024, reaching CHF 1,121 million, a result that has sharpened investor attention on the stock. See our latest analysis for BELIMO Holding. Despite a recent 1-day share price return of 0.79% decline and a 7-day share price return of 2.06% decline, BELIMO Holding’s 12.49% 30-day share price return and 26.56% 1-year total shareholder...

As the European markets show resilience with the STOXX Europe 600 Index ending higher, supported by robust economic data and earnings results, investors are keenly observing opportunities for undervalued stocks amidst mixed performances across major indices. In this context, identifying stocks trading below their intrinsic value can be a strategic move for those looking to capitalize on potential market inefficiencies.

In January 2026, Sandoz confirmed that the European Commission had granted marketing authorization for Ondibta®, a biosimilar insulin glargine pre-filled pen for patients with diabetes aged two and above, matching Lantus® SoloStar® in safety, quality and efficacy. This approval, under Sandoz’s commercialization agreement with Gan & Lee, reinforces its biosimilar footprint in diabetes care and supports broader access to insulin across Europe. We will now examine how this European Commission...

If you are wondering whether Novartis shares offer solid value at today’s price, this article will walk through what the current market is actually paying for the business. Novartis recently closed at $115.10, with returns of 0.5% over 7 days, 4.5% over 30 days, 6.1% year to date, 32.1% over 1 year, 64.6% over 3 years and 77.8% over 5 years. This gives useful context before you weigh up the valuation. Recent attention on Novartis has been shaped by ongoing product pipeline developments and...